Eli Lilly and Evidation expand digital biomarker collaboration by Conor Hale Friday, December 14, 2018 Eli Lilly expanded its work with Evidation Health in developing digital biomarkers derived from smartphones, wearable sensors and voice data.
Parexel and Eli Lilly team to bolster clinical trials in China by Joseph Keenan Wednesday, December 12, 2018 Parexel partnering with Eli Lilly to support building a clinical trial learning and development program in China.
Lilly pays AC $81M upfront for preclinical Alzheimer’s drug by Nick Paul Taylor Wednesday, December 12, 2018 The deal gives Lilly ownership of a small molecule that has inhibited tau aggregation in preclinical models.
Alkermes’ schizophrenia drug hits the mark in phase 3 by Amirah Al Idrus Thursday, November 29, 2018 Patients taking ALKS-3831 gained less weight on average than patients taking olanzapine, the antipsychotic on which it is based.
Genentech’s inhaled JAK1 inhibitor shows promise in asthma by Angus Liu Wednesday, November 21, 2018 Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.
Lilly marketing officer to join Brickell Bio as CEO by Conor Hale Monday, November 19, 2018 Eli Lilly VP Robert Brown is making the jump to serve as CEO of the skin disease-focused Brickell Biotech.
Lilly files for FDA approval of migraine drug lasmiditan by Nick Paul Taylor Wednesday, November 14, 2018 Lilly is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug can clear headache pain in two hours.
